Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials

Authors

Alan Barker

Published

August 18, 2014

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Respiratory Medicine

Topics

DOI

10.1016/s2213-2600(14)70165-1

Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials

Authors

Alan Barker

Published

August 18, 2014

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Respiratory Medicine

Topics

DOI

10.1016/s2213-2600(14)70165-1

Paper

Paper

Paper

Paper

Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials

Abstract

Supporters

Journal

Topics

DOI

Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials

Abstract

Supporters

Journal

Topics

DOI